Pharmacokinetics of Dasatinib for Philadelphia- Positive Acute Lymphocytic Leukemia with Acquired T315I mutation

Journal of Hematology & Oncology, 05/16/2012

The data indicate that the emergence of the T315I mutation among Philadelphia–positive acute lymphoid leukemia (Ph+ALL) patients patients treated with dasatinib is, in part, dependent on plasma dasatinib pharmacokinetics. Notably, these data also suggest that newly acquired BCR–ABL mutations may be inhibited by an increased exposure of dasatinib.

Print Article Summary Cat 2 CME Report